Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Technology to Improve Glucose Control in Participants With Type 1 Diabetes

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Other: Meal-Tagging App
Device: Fitness Tracker

First Posted Date: 2018-11-29

Last Posted Date: 2020-08-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 28

Registration Number: NCT03758430

Locations: 🇺🇸
Joslin Diabetes Center, Boston, Massachusetts, United States

A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis

Phase 1

Completed

Conditions: Dermatitis, Atopic

Interventions: Drug: LY3454738
Drug: Placebo

First Posted Date: 2018-11-23

Last Posted Date: 2021-10-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 128

Registration Number: NCT03750643

Locations: 🇺🇸
Global Health Research Center, Miami Lakes, Florida, United States
🇺🇸
PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore, Maryland, United States
🇺🇸
Revival Research Corporation, Doral, Florida, United States

and more 18 locations

A Study of LY3415244 in Participants With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Drug: LY3415244

First Posted Date: 2018-11-23

Last Posted Date: 2021-10-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 12

Registration Number: NCT03752177

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵
National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan

and more 3 locations

Study of LY3074828 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3074828
Drug: Placebo
Drug: LY900021

First Posted Date: 2018-11-21

Last Posted Date: 2019-07-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT03748940

Locations: 🇬🇧
Covance Clinical Research Ltd, Leeds, West Yorkshire, United Kingdom

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)

Not Applicable

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Device: AID System
Drug: Insulin Lispro

First Posted Date: 2018-11-16

Last Posted Date: 2019-02-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 10

Registration Number: NCT03743285

Locations: 🇺🇸
Rainier Clinical Research Center, Renton, Washington, United States

A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

Phase 2

Terminated

Conditions: Primary Biliary Cholangitis

Interventions: Drug: Placebo
Drug: Baricitinib

First Posted Date: 2018-11-15

Last Posted Date: 2020-10-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2

Registration Number: NCT03742973

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
UH Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

and more 9 locations

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes

Phase 3

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: LY900014
Drug: Insulin Lispro
Drug: Insulin Glargine
Drug: Insulin Degludec

First Posted Date: 2018-11-14

Last Posted Date: 2022-01-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 751

Registration Number: NCT03740919

Locations: 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸
Children's Hospital Los Angeles - Dept of Endocrinology, Los Angeles, California, United States
🇺🇸
University of Arizona, Tucson, Arizona, United States

and more 108 locations

A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: LY3209590
Drug: Insulin Degludec

First Posted Date: 2018-11-09

Last Posted Date: 2021-03-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 399

Registration Number: NCT03736785

Locations: 🇺🇸
John Muir Physician Network Clinical Research Center, Concord, California, United States
🇺🇸
Valley Endocrine, Fresno, Fresno, California, United States
🇺🇸
National Research Institute, Los Angeles, California, United States

and more 39 locations

A Study of LY3090106 in Japanese and Caucasian Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: LY3090106

First Posted Date: 2018-11-09

Last Posted Date: 2019-05-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT03736772

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Baricitinib
Drug: Topical corticosteroid
Drug: Placebo

First Posted Date: 2018-11-07

Last Posted Date: 2020-08-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 329

Registration Number: NCT03733301

Locations: 🇩🇪
Charité Universitätsmedizin Berlin, Berlin, Germany
🇯🇵
Kawashima Dermatology Clinic, Ichikawa-shi, Chiba, Japan
🇯🇵
Yamano Dermatological Clinic, Dazaifu, Fukuoka, Japan

and more 65 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy